X4 Pharmaceuticals Framtida tillväxt
Future kriterier kontrolleras 2/6
X4 Pharmaceuticals förväntas öka vinsten och intäkterna med 50.2% och 66.7% per år respektive medan EPS förväntas växa med 56.3% per år.
Viktig information
50.2%
Tillväxttakt i vinsten
56.28%
Tillväxttakt för EPS
| Biotechs vinsttillväxt | 25.1% |
| Intäkternas tillväxttakt | 66.7% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 02 Jun 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • Jun 17
XFOR: Chronic Neutropenia Opportunity Will Drive Future Stock Upside Potential
Analysts have raised their 12 month price target on X4 Pharmaceuticals stock from $10 to $12, citing a more constructive view of the company’s lead program mavorixafor and its potential in the large, underpenetrated chronic neutropenia market. What’s in the News for X4 Pharmaceuticals X4 Pharmaceuticals received European Commission marketing authorization for XOLREMDI (mavorixafor) capsules to treat patients aged 12 and older with WHIM syndrome in the European Union, following a positive opinion from the EMA’s Committee for Medicinal Products for Human Use.
Uppdatering av berättelse • Jun 03
XFOR: Chronic Neutropenia Opportunity Will Drive Future Upside Potential
Narrative Update on X4 Pharmaceuticals The consensus analyst price target for X4 Pharmaceuticals has moved to $12, with analysts pointing to the potential of lead drug mavorixafor in chronic neutropenia and WHIM syndrome as the main factor in their valuation analysis. Analyst Commentary Bullish analysts are highlighting X4 Pharmaceuticals as a focused rare disease story centered on mavorixafor, with both chronic neutropenia and WHIM syndrome at the core of their views.
Uppdatering av berättelse • May 20
XFOR: Single Asset CXCR4 Platform Is Poised To Drive Upside
Analysts have lifted their price target on X4 Pharmaceuticals to $11.67 from $8.00, citing a stronger outlook for mavorixafor as a potential first in class oral CXCR4 antagonist in WHIM syndrome and primary chronic neutropenia. They note that the current valuation does not fully reflect its role as the company's key value driver.Uppdatering av berättelse • May 04
XFOR: Single CXCR4 Hematology Program Will Drive Future Upside Potential
Analysts have raised their price target on X4 Pharmaceuticals to $12, citing what they view as significant upside potential from mavorixafor as a key value driver for WHIM syndrome and primary chronic neutropenia, along with a current valuation that they see as not fully reflecting this opportunity. Analyst Commentary Recent Street research frames X4 Pharmaceuticals as a focused hematology company, with attention centered on mavorixafor as a potential first in class oral CXCR4 antagonist for WHIM syndrome and primary chronic neutropenia.Uppdatering av berättelse • Apr 20
XFOR: CXCR4 Program In WHIM And Chronic Neutropenia Will Drive Future Upside
Analysts have reset their price target on X4 Pharmaceuticals to $12, citing Guggenheim's recent initiation, which highlights mavorixafor as a key value driver in WHIM syndrome and primary chronic neutropenia. Analyst Commentary The latest Street research frames X4 Pharmaceuticals as closely tied to the success of mavorixafor in WHIM syndrome and primary chronic neutropenia.Uppdatering av berättelse • Apr 05
XFOR: Mavorixafor Franchise Is Expected To Drive Future Upside Potential
Narrative Update Analysts have raised their price target for X4 Pharmaceuticals to $12, citing the perceived upside in mavorixafor as a key value driver and updating fair value assumptions to $10.00, along with adjusted growth, margin, discount rate, and future P/E inputs. Analyst Commentary Recent research points to mavorixafor as the central piece of the X4 Pharmaceuticals story, with coverage initiating at a $12 price target that aligns with the view of the drug as a key value driver.Uppdatering av berättelse • Mar 22
XFOR: WHIM And Chronic Neutropenia Program Will Drive Future Upside
Analysts have adjusted their price target on X4 Pharmaceuticals to $12, noting what they view as potential upside tied to mavorixafor as a key value driver in WHIM syndrome and primary chronic neutropenia. Analyst Commentary Recent commentary from bullish analysts centers on how mavorixafor could reshape the risk reward profile for X4 Pharmaceuticals, especially as the program advances in WHIM syndrome and primary chronic neutropenia.Uppdatering av berättelse • Mar 07
XFOR: EU WHIM Decision And Chronic Neutropenia Program Will Drive Upside Potential
Analysts have reset their price target for X4 Pharmaceuticals to $13.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that they see as better aligned with the company’s current risk and earnings profile. What's in the News The European Medicines Agency's CHMP adopted a positive opinion recommending marketing authorization, under exceptional circumstances, for mavorixafor to treat WHIM syndrome in the EU (Key Developments).Uppdatering av berättelse • Feb 21
XFOR: Higher Fair Value Will Reflect Stronger Outlook Despite Margin Headwinds
Analysts have lifted their fair value estimate for X4 Pharmaceuticals from $4.00 to $5.00 per share, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E as key drivers of the new price target. Valuation Changes Fair Value was raised from $4.00 to $5.00 per share, an increase of 25% in the modelled estimate.Uppdatering av berättelse • Feb 06
XFOR: Fair Value View Will Balance Dilution Concerns And Execution Milestones
Analysts have lifted their price target on X4 Pharmaceuticals to $4.00 per share from $4.00, citing updated assumptions around revenue growth, discount rate, profit margin, and future P/E that are now reflected in their models. Valuation Changes Fair Value: Maintained at $4.00 per share, with no change from the prior estimate.Uppdatering av berättelse • Jan 23
XFOR: Future Outlook Weighs October Financing Dilution Against Execution And Earnings Milestones
Narrative Update Analysts have trimmed their 12 month price target on X4 Pharmaceuticals to US$7.50 from US$9.00, mainly reflecting updated financing assumptions after the recent earnings report and the October capital raise. Analyst Commentary Bearish analysts are using the latest earnings report and the October capital raise to reset expectations on X4 Pharmaceuticals, with the 12 month price target update to US$7.50 at the center of their view.Uppdatering av berättelse • Jan 09
XFOR: Future Outlook Balances October Financing Dilution With Execution And Earnings Milestones
Analysts have trimmed their 12 month price target for X4 Pharmaceuticals to US$7.50 from US$9.00, citing updated financing assumptions following the October capital raise as well as recent earnings and corporate updates. Analyst Commentary Bearish analysts are framing the lower US$7.50 12 month price target as a reset that reflects updated expectations after recent earnings and the October capital raise.Analysartikel • Dec 24
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon
With a median price-to-sales (or "P/S") ratio of close to 12.4x in the Biotechs industry in the United States, you...Uppdatering av berättelse • Dec 22
XFOR Future Outlook Weighs Financing Dilution Against Long Term Commercial Upside
Analysts have trimmed their price target on X4 Pharmaceuticals by $1.50 to $7.50, citing updated models that factor in revised financing assumptions following the company’s recent earnings report and October capital raise. Analyst Commentary Bearish analysts have pointed to the latest target cut as evidence that X4 Pharmaceuticals faces a more challenging path to value creation than previously modeled, with revised financing assumptions weighing on upside potential.Uppdatering av berättelse • Dec 07
XFOR: Recent Financing Will Support Key Phase 3 Progress And Upside Potential
Analysts have modestly trimmed their fair value estimate for X4 Pharmaceuticals, cutting the price target from $9.00 to $7.50, as updated models incorporate revised financing assumptions following the company's recent capital raise. Analyst Commentary Analyst updates following the latest earnings report and corporate update emphasize that the lower price target is primarily a function of revised financing assumptions rather than a fundamental shift in the long term outlook for X4 Pharmaceuticals.Uppdatering av berättelse • Nov 23
XFOR: Leadership Overhaul And Fresh Capital Will Drive Pipeline Progress
Analysts have revised their price target for X4 Pharmaceuticals downward from $8.70 to $7.38. They cite updated financing assumptions and recent corporate developments as key factors behind the adjustment.Uppdatering av berättelse • Sep 25
US Launch And EMA Approval Will Expand Global Reach
Amid leadership changes and a recapitalization that add near-term execution risk despite long-term potential for mavorixafor in a substantial unmet market, analysts have lowered their price target for X4 Pharmaceuticals from $19.75 to $8.70. Analyst Commentary Leadership overhaul and new senior management introduce execution uncertainty but may improve strategic direction.Uppdatering av berättelse • Sep 02
US Launch And EMA Approval Will Expand Global Reach
Analysts have lowered their price target for X4 Pharmaceuticals from $23.25 to $19.75, citing increased execution risks and near-term uncertainty from a leadership overhaul, tempered by optimism over recent recapitalization and the long-term potential of mavorixafor. Analyst Commentary Recent complete overhaul of the senior leadership team introduces uncertainty but also the potential for strategic renewal.Uppdatering av berättelse • Aug 19
US Launch And EMA Approval Will Expand Global Reach
A significant reduction in X4 Pharmaceuticals’ future P/E signals lower growth expectations or improved earnings outlook, while a decreased discount rate indicates lower perceived risk, contributing to a sharp downward revision in the fair value estimate from $41.08 to $23.25. What's in the News X4 Pharmaceuticals completed a private placement, issuing 11,040,776 shares at $1.42 and 48,852,772 pre-funded warrants at $1.419, raising $85 million, led by Coastlands Capital LP and supported by top life science investors.Analysartikel • Aug 12
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Revenues Are Not Doing Enough For Some Investors
You may think that with a price-to-sales (or "P/S") ratio of 0.3x X4 Pharmaceuticals, Inc. ( NASDAQ:XFOR ) is...
Ny berättelse • Mar 30
US Launch And EMA Approval Will Expand Global Reach
The transition to a commercial-stage pharmaceutical and strategic international partnerships could significantly boost revenue growth and international market presence.Seeking Alpha • Jul 02
X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
Summary X4 Pharmaceuticals, Inc. stock price dropped due to the discontinuation of Phase II study for chronic neutropenia, but the potential market for mavorixafor is substantial. X4 Pharmaceuticals is targeting rare diseases with mavorixafor, approved for WHIM syndrome, and moving forward with a Phase III trial for CN. X4 Pharmaceuticals has the potential for significant growth with mavorixafor addressing multiple rare diseases, but faces risks including FDA approval and market penetration. I discuss why I am attempting to "catch the falling knife." Read the full article on Seeking AlphaAnalysartikel • Mar 26
Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysartikel • Apr 19
Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Oct 07
Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 101 | -110 | -76 | -76 | 3 |
| 12/31/2027 | 10 | -117 | -83 | -83 | 4 |
| 12/31/2026 | 10 | -98 | -83 | -82 | 4 |
| 3/31/2026 | 9 | -100 | -93 | -93 | N/A |
| 12/31/2025 | 35 | -79 | -89 | -86 | N/A |
| 9/30/2025 | 34 | -95 | -106 | -103 | N/A |
| 6/30/2025 | 33 | -102 | -112 | -109 | N/A |
| 3/31/2025 | 31 | 15 | -120 | -110 | N/A |
| 12/31/2024 | 3 | -37 | -138 | -131 | N/A |
| 9/30/2024 | 1 | -17 | -133 | -126 | N/A |
| 6/30/2024 | 1 | 18 | -120 | -112 | N/A |
| 3/31/2024 | N/A | -129 | -104 | -104 | N/A |
| 12/31/2023 | N/A | -101 | -97 | -97 | N/A |
| 9/30/2023 | N/A | -111 | -88 | -88 | N/A |
| 6/30/2023 | N/A | -131 | -86 | -86 | N/A |
| 3/31/2023 | N/A | -96 | -83 | -83 | N/A |
| 12/31/2022 | N/A | -96 | -77 | -77 | N/A |
| 9/30/2022 | N/A | -103 | -77 | -77 | N/A |
| 6/30/2022 | N/A | -102 | -72 | -72 | N/A |
| 3/31/2022 | N/A | -100 | -73 | -73 | N/A |
| 12/31/2021 | N/A | -103 | -72 | -71 | N/A |
| 9/30/2021 | N/A | -85 | -70 | -69 | N/A |
| 6/30/2021 | N/A | -82 | -71 | -69 | N/A |
| 3/31/2021 | N/A | -78 | -63 | -62 | N/A |
| 12/31/2020 | 3 | -62 | -60 | -59 | N/A |
| 9/30/2020 | 3 | -55 | -52 | -51 | N/A |
| 6/30/2020 | 3 | -55 | -50 | -49 | N/A |
| 3/31/2020 | 3 | -53 | -53 | -52 | N/A |
| 12/31/2019 | N/A | -53 | N/A | -48 | N/A |
| 9/30/2019 | N/A | -55 | N/A | -46 | N/A |
| 6/30/2019 | N/A | -46 | N/A | -39 | N/A |
| 3/31/2019 | N/A | -40 | N/A | -31 | N/A |
| 12/31/2018 | N/A | -36 | N/A | -25 | N/A |
| 9/30/2018 | N/A | -31 | N/A | -23 | N/A |
| 12/31/2017 | N/A | -25 | N/A | -21 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: XFOR förväntas förbli olönsam under de kommande 3 åren.
Resultat vs marknad: XFOR förväntas förbli olönsam under de kommande 3 åren.
Höga tillväxtresultat: XFOR förväntas förbli olönsam under de kommande 3 åren.
Intäkt vs marknad: XFOR s intäkter ( 66.7% per år) förväntas växa snabbare än US marknaden ( 12.7% per år).
Hög tillväxtintäkter: XFOR s intäkter ( 66.7% per år) förutspås växa snabbare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om XFOR s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/06 22:26 |
| Aktiekurs vid dagens slut | 2026/07/06 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
X4 Pharmaceuticals, Inc. bevakas av 9 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Leah Rush Cann | Brookline Capital Markets |
| Arlinda Lee | Canaccord Genuity |
| Michael Schmidt | Guggenheim Securities, LLC |